Neoisoliquiritigenin
(Synonyms: 新异甘草苷) 目录号 : GC38981
Neoisoliquiritigenin，分离于 Spatholobus suberectus 中，Neoisoliquiritigenin 直接结合 GRP78 调节 β-catenin 途径，抑制乳腺癌细胞增殖并诱导细胞凋亡
Cas No.:7014-39-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Neoisoliquiritigenin, isolated from Spatholobus suberectus, inhibits cell proliferation and induced cell apoptosis in breast cancer by directly binding to GRP78 to regulate the β-catenin pathway[1][2].
[1]. Tang H, et al. Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer.Curr Cancer Drug Targets. 2018;18(4):390-399.
| Cas No. | 7014-39-3 | SDF | |
| 别名 | 新异甘草苷 | ||
| Canonical SMILES | O=C(C(C=CC(O)=C1)=C1O)/C=C/C2=CC=C(C=C2)O[C@H]3O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]3O | ||
| 分子式 | C21H22O9 | 分子量 | 418.39 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3901 mL | 11.9506 mL | 23.9011 mL |
| 5 mM | 0.478 mL | 2.3901 mL | 4.7802 mL |
| 10 mM | 0.239 mL | 1.1951 mL | 2.3901 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Curr Cancer Drug Targets 2018;18(4):390-399.PMID:28914191DOI:10.2174/1568009617666170914155355.
Background: Breast cancer mortality has been stable or decreasing in the world, its incidence and recurrence rates have sharply risen worldwide in the recent years. Objective: To investigate the clinicopathological significance and potential function of GRP78 in the development and progression of breast cancer. To explore the effects of Neoisoliquiritigenin (NISL) in breast cancer and the underlying mechanism. Method: GRP78 was detected by immunohistochemistry (IHC) using breast cancer tissue microarrays (TMAs), and the association between GRP78 levels and clinicopathological factors and prognosis was analyzed. The functional effects of GRP78 on breast cancer were validated by an MTT assay, foci formation assay, Matrigel invasion assay and mouse xenograft assay. The effects of NISL were tested by an MTT assay, apoptosis assay and mouse xenograft assay. A LigandFit algorithm, ATPase activity assay, western blot and IHC assay were used to discover the underlying mechanism of the effects of NSIL. Results: GRP78 was highly expressed in breast cancer cell lines and tissues. In addition, high expression of GRP78 was correlated to poor outcomes and distant metastasis. Functional experiments showed that GRP78 promoted breast cancer proliferation and invasion in vitro and in vivo. NISL inhibited cell proliferation and induced cell apoptosis in breast cancer by directly binding to GRP78 to regulate the β-catenin pathway. Conclusion: Taken together, these results highlighted the significance of GRP78 in breast cancer development and suggested NISL as a natural candidate to inhibit breast cancer by targeting GRP78 and β-catenin signaling.
The application of HPLC-MS/MS to studies of pharmacokinetics and interconversion of isoliquiritigenin and Neoisoliquiritigenin in rats
Biomed Chromatogr 2016 Jul;30(7):1155-1161.PMID:26577957DOI:10.1002/bmc.3655.
A specific and sensitive HPLC-MS/MS method was developed and validated for the simultaneously quantification of isoliquiritigenin (ISL) and neoisoliquiritin (NIS) in rat plasma by oral administration. Analytes were analyzed on an Agilent 6460 LC-MS/MS system (Agilent, USA) using an Agilent Zorbax SB-C18 column (4.6 × 150 mm, 5 μm). Gradient elution was applied for the analyte separation using a mobile phase composed of 0.1% formic acid aqueous solution and methanol at a flow rate of 1.0 mL/min with a total running time of 12 min. The calibration curves for ISL and NIS showed good linearity in the concentrations ranging from 0.001 to 4.000 μg/mL with correlation coefficients >0.998. The precision, accuracy, recovery and stability were deemed acceptable. The method was applied to the pharmacokinetics study of ISL and NIS in rats by single and combination administration. The result showed that Cmax and AUC0→t of ISL were markedly increased from 0.53 to 1.20 μg/mL, and from 69.63 to 200.74 min μg/mL by combination administration. The mean t1/2 value was also prolonged from 64.55 to 203.74 min in the combination group. These results indicated that NIS may have been metabolized to ISL which increased the absorption and extended the elimination of ISL. However, little difference was found for NIS pharmacokinetics parameters between single NIS and the combination group, which suggested that there was no significant biotransformation of ISL to NIS. Copyright © 2015 John Wiley & Sons, Ltd.
Bioactive constituents of Spatholobus suberectus in regulating tyrosinase-related proteins and mRNA in HEMn cells
Phytochemistry 2006 Jun;67(12):1262-70.PMID:16782143DOI:10.1016/j.phytochem.2006.05.008.
Spatholobus suberectus Dunn (Leguminosae) is a traditional Chinese herbal medicine used to treat rheumatism, anemia, menoxenia, and other disorders. The extent to which this herbal medicine is useful to skin cells, however, has not been evaluated. Constituents of the 95% ethanol extracts of the dried vine stems of S. suberectus were therefore isolated and examined for their skin-whitening capacity. A bio-guided phytochemical investigation, involving use of the mushroom tyrosinase inhibitory system, of active fractions of the extracts resulted in the isolation of 12 constituents. The structures of these constituents, which were characterized by various spectroscopic techniques, consisted of one flavone, three isoflavones, five flavanones, two flavanonols, and one chalcone. Of these constituents 3',4',7-trihydroxyflavone (1), eriodictyol (3), plathymenin (5), dihydroquercetin (6), butin (7), Neoisoliquiritigenin (8), dihydrokaempferol (9), liquiritigenin (10), and 6-methoxyeriodictyol (12) represented compounds isolated for the first time from S. suberectus. These constituents were evaluated their ability to inhibit cellular tyrosinase activity and for their melanin inhibitory activity in human epidermal melanocytes (HEMn). Butin (7) was the most efficacious of these constituents and exhibited concentration-dependent effects. Western blot analysis revealed that expression of tyrosinase and tyrosinase-related proteins 1 and 2 (TRP1 and TRP2) was decreased in butin (7)-treated HEMn cells. Additionally, quantitative real-time PCR (qRT-PCR) analysis disclosed that expression of mRNAs for tyrosinase, TRP1 and TRP2 was suppressed by butin (7). It is concluded that butin (7) is the most active of the components of S. suberectus in inhibiting pigmentation and that this inhibition is exerted through inhibition of transcription of the genes encoding tyrosinase, TRP1 and TRP2.